Lasmiditan5-HT1F receptor agonist CAS# 439239-90-4 |
- CUDC-101
Catalog No.:BCC2149
CAS No.:1012054-59-9
- Valproic acid sodium salt (Sodium valproate)
Catalog No.:BCC2156
CAS No.:1069-66-5
- M344
Catalog No.:BCC2162
CAS No.:251456-60-7
- Belinostat (PXD101)
Catalog No.:BCC2153
CAS No.:414864-00-9
- Trichostatin A (TSA)
Catalog No.:BCC3605
CAS No.:58880-19-6
- JNJ-26481585
Catalog No.:BCC2147
CAS No.:875320-29-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 439239-90-4 | SDF | Download SDF |
PubChem ID | 11610526 | Appearance | Powder |
Formula | C19H18F3N3O2 | M.Wt | 377.36 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in DMSO | ||
Chemical Name | 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide | ||
SMILES | CN1CCC(CC1)C(=O)C2=NC(=CC=C2)NC(=O)C3=C(C=C(C=C3F)F)F | ||
Standard InChIKey | XEDHVZKDSYZQBF-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Lasmiditan Dilution Calculator
Lasmiditan Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.65 mL | 13.2499 mL | 26.4999 mL | 52.9998 mL | 66.2497 mL |
5 mM | 0.53 mL | 2.65 mL | 5.3 mL | 10.6 mL | 13.2499 mL |
10 mM | 0.265 mL | 1.325 mL | 2.65 mL | 5.3 mL | 6.625 mL |
50 mM | 0.053 mL | 0.265 mL | 0.53 mL | 1.06 mL | 1.325 mL |
100 mM | 0.0265 mL | 0.1325 mL | 0.265 mL | 0.53 mL | 0.6625 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Lasmiditan is a selective agonist of 5-HT1F receptor with Ki value of 2.21nM [1].
Lasmiditan shows great selectivity against 5-HT1F over other human recombinant 5-HT receptor subtypes as well as other members of 5-HT1 family. The Ki values for 5-HT2A-2C, 5-HT6 and 5-HT7 are all above 2μM. In the in vitro functional assay, lasmiditan shows high functional selectivity for 5-HT1F with EC50 value of 43.1nM. Moreover, oral administration of lasmiditan potently decreases the dural plasma protein extravasation with ID50 value of 2×104μg/kg in the migraine models. It also inhibits trigeminal stimulation-induced c-fos expression in the nucleus caudalis. Furthermore, lasmiditan is proved to be an effective treatment in acute migraine after the phase II trials. And the oral administration is found to be better than the intravenous administration [1, 2]
References:
[1] Nelson D L, Phebus L A, Johnson K W, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia, 2010, 30(10): 1159-1169.
[2] Tfelt-Hansen P C, Olesen J. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. The journal of headache and pain, 2012, 13(4): 271-275.
- Bay 60-7550
Catalog No.:BCC1405
CAS No.:439083-90-6
- Afatinib
Catalog No.:BCC3656
CAS No.:439081-18-2
- O-2093
Catalog No.:BCC7070
CAS No.:439080-01-0
- Gentianine
Catalog No.:BCN5492
CAS No.:439-89-4
- 2-Amino-3-methylbenzoic acid
Catalog No.:BCC8528
CAS No.:4389-45-1
- JIP-1 (153-163)
Catalog No.:BCC5777
CAS No.:438567-88-5
- 3(20)-Phytene-1,2-diol
Catalog No.:BCN6589
CAS No.:438536-34-6
- PFK-015
Catalog No.:BCC5280
CAS No.:4382-63-2
- Perakine
Catalog No.:BCN5491
CAS No.:4382-56-3
- Robtin
Catalog No.:BCN5490
CAS No.:4382-34-7
- Dihydrorobinetin
Catalog No.:BCN5489
CAS No.:4382-33-6
- Quercetin 3,3'-dimethyl ether
Catalog No.:BCN7781
CAS No.:4382-17-6
- GW 627368
Catalog No.:BCC7961
CAS No.:439288-66-1
- ITK inhibitor
Catalog No.:BCC1662
CAS No.:439574-61-5
- BMS-509744
Catalog No.:BCC1424
CAS No.:439575-02-7
- NPY 5RA972
Catalog No.:BCC7747
CAS No.:439861-56-0
- Gnetifolin M
Catalog No.:BCN3394
CAS No.:439900-84-2
- Isoscabertopin
Catalog No.:BCN4634
CAS No.:439923-16-7
- Trifluoperazine 2HCl
Catalog No.:BCC4384
CAS No.:440-17-5
- K 579
Catalog No.:BCC2364
CAS No.:440100-64-1
- WAY 200070
Catalog No.:BCC7669
CAS No.:440122-66-7
- 3-Phenyl-2-propen-1-ol
Catalog No.:BCN5493
CAS No.:4407-36-7
- Benzoin oxime
Catalog No.:BCC8858
CAS No.:441-38-3
- Eribulin mesylate
Catalog No.:BCC5173
CAS No.:441045-17-6
Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan.[Pubmed:24729708]
Neuropsychiatr Dis Treat. 2014 Mar 31;10:547-52.
The serotonin receptor agonist triptan drugs (5-HT1B/1D receptor agonists) have been in use for over 20 years in the abortive management of migraine. Although clearly effective, their ability to produce vasoconstriction in cerebral and coronary arteries, thought to be mediated by their high affinity for the 5-HT1B receptor, has been a limitation to their use in certain patient populations. Variable potency triptan binding at the 5-HT1F receptor occurs in addition to binding at the 5-HT1B and 5-HT1D receptors. A more selective serotonin agonist without 5-HT1B-mediated vasoconstriction might prove efficacious yet safer. The 5-HT1F receptor has been targeted as a site of action for such a drug. In experimental models, 5-HT1F receptor agonists have been shown to block neurogenic inflammation and c-Fos expression in neural tissue and, as well, show no evidence of vasoconstriction in vascular tissue models in vitro. In clinical trials, efficacy in the abortive management of migraine has been established. Lasmiditan (LY573144), a selective 5-HT1F receptor agonist (K1=2.21 muM), showed efficacy in its primary endpoint, with a 2-hour placebo-subtracted headache response of 28.8%, though with frequent reports of dizziness, paresthesias, and vertigo. Study results support an emerging central neuronal mechanism of migraine pathophysiology. This review traces the history and use of 5-HT1F receptor agonists, now referred to as neurally acting anti-migraine agents in migraine management.
Lasmiditan for the treatment of migraine.[Pubmed:28076702]
Expert Opin Investig Drugs. 2017 Feb;26(2):227-234.
INTRODUCTION: Migraine is one of the most common diseases in the world, with high economical and subjective burden. Migraine acute therapy is nowadays based on specific and non-specific drugs but up to 40% of episodic migraineurs still have unmet treatment needs and over 35% do not benefit from triptans administration. Serotonin-1F receptors have been identified in trigeminal system and became an ideal target for anti-migraine drug development as potential trigeminal neural inhibitors. Lasmiditan, a novel serotonin1F receptor agonist, showed specific affinity in vitro for the receptor without any vasoconstrictive action and inhibited markers associated with electrical stimulation of trigeminal ganglion in migraine animal models. Areas covered: This article reviews both preclinical and clinical studies on Lasmiditan as a potential acute therapy for migraine, as well as pharmacokinetic and pharmacodynamic features. It also summarizes safety and tolerability data gathered in the various human studies. Expert opinion: The absence of vasoconstrictive effects makes Lasmiditan a promising novel migraine acute therapy. Although preclinical and Phase I and II studies established a significant efficacy, the limited knowledge about pharmacokinetics and metabolism, the high rate of non-serious central nervous system side effects and the lack of larger studies remain still a matter of concern that should be addressed in future studies.
Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.[Pubmed:22459549]
Lancet Neurol. 2012 May;11(5):405-13.
BACKGROUND: Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. We aimed to assess the efficacy and safety of oral Lasmiditan for the acute treatment of migraine. METHODS: In this multicentre, double-blind, parallel-group, dose-ranging study in 43 headache centres in five European countries, patients with migraine with and without aura and who were not using prophylaxis were randomly assigned (1:1:1:1:1) to treat one moderate or severe attack at home with 50 mg, 100 mg, 200 mg, or 400 mg Lasmiditan, or placebo. Study drug and placebo were supplied in identical numbered tablet packs. The randomisation code was generated by an independent statistician. Patients and investigators were masked to treatment allocation. The primary endpoint was dose response for headache relief (moderate or severe becoming mild or none) at 2 h. The primary analysis was done in the modified intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00883051. FINDINGS: Between July 8 2009, and Feb 18, 2010, 512 patients were randomly assigned to treatment, 391 of whom received treatment. 86 patients received placebo (81 included in primary analysis) and 305 received Lasmiditan (50 mg n=79, 100 mg n=81, 200 mg n=69, and 400 mg n=68 included in primary analysis). There was a linear association between headache response rate at 2 h and Lasmiditan dose (Cochran-Armitage test p<0.0001). Every Lasmiditan treatment dose significantly improved headache response at 2 h compared with placebo (Lasmiditan 50 mg: difference 17.9%, 95% CI 3.9-32.1, p=0.022; 100 mg: 38.2%, 24.1-52.4, p<0.0001; 200 mg: 28.8%, 9.6-39.9, p=0.0018; 400 mg: 38.7%, 23.9-53.6, p<0.0001). The proportion of patients with treatment-emergent adverse events increased with increasing doses (53/82 [65%], 59/82 [72%], 61/71 [86%], and 59/70 [84%] for Lasmiditan 50, 100, 200, and 400 mg, respectively vs 19/86 [22%] for placebo). Most adverse events were mild or moderate in intensity, with 16 of 82 (20%), 23 of 82 (28%), 28 of 71 (39%), and 31 of 70 (44%) of patients on Lasmiditan 50, 100, 200, and 400 mg, respectively reporting a severe adverse event compared with five of 86 (6%) on placebo. The most common adverse events were CNS related and included dizziness, fatigue, vertigo, paraesthesia, and somnolence. INTERPRETATION: Oral Lasmiditan seems to be safe and effective in the acute treatment of migraine. Further assessment in larger placebo-controlled and triptan-controlled trials are needed to assess the potential role of Lasmiditan in acute migraine therapy. FUNDING: CoLucid Pharmaceuticals.
The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine.[Pubmed:25584073]
Ther Adv Neurol Disord. 2015 Jan;8(1):46-54.
More than 20 years have passed without the launch of a new substance class for acute migraine therapy. Triptans were the latest class of substances which successfully passed all developmental stages with a significant antimigraine efficacy and a sufficient safety profile. New drugs with a better adverse event profile and at least similar efficacy are needed for migraine subjects who cannot tolerate triptans for attack treatment. Lasmiditan is a novel highly specific 5-HT1F receptor agonist currently in clinical trials for acute migraine therapy and devoid of vasoconstriction in coronary arteries as determined in a surrogate assay. In both phase II randomized, placebo-controlled trials in acute migraine the primary endpoint was met. For the intravenous formulation a clear dose-dependent effect on headaches could be determined. Lasmiditan tablets in doses of 50-400 mg show significant headache relief after 2 hours compared with placebo and improved accompanying symptoms. This substance is chemically clearly different from other antimigraine drugs, which is also reflected by its dose-dependent adverse event profile chiefly including dizziness, vertigo, paresthesia and fatigue. Adverse events are usually linked to the central nervous system. Future phase III clinical trials with an active triptan comparator or in a preferential trial design will allow a better comparison of Lasmiditan and triptans. They will also determine whether Lasmiditan will become available to the migraine patient.